Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (611-620 of 754) with videos related to

Pageof 76
Sort By:
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
ESC Heart Failure|October 9, 2023
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartanJawad H Butt, Kirsty McDowell, Toru Kondo, et al.
NEJM Catalyst Innovations in Care Delivery|July 8, 2026
Optimizing Enterprise Referral Processing through Automated Fax TriageDavid Mui, Jennifer L A Tran, Sharon Onofre, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
JACC. Heart Failure|June 6, 2024
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m<sup>2</sup>Safia Chatur, Iris E Beldhuis, Brian L Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Pageof 76

Showing results (611-620 of 754) with videos related to

Sort By:
Pageof 76
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
ESC Heart Failure|October 9, 2023
Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartanJawad H Butt, Kirsty McDowell, Toru Kondo, et al.
NEJM Catalyst Innovations in Care Delivery|July 8, 2026
Optimizing Enterprise Referral Processing through Automated Fax TriageDavid Mui, Jennifer L A Tran, Sharon Onofre, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
JACC. Heart Failure|June 6, 2024
Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m<sup>2</sup>Safia Chatur, Iris E Beldhuis, Brian L Claggett, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 4, 2015
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)David M Charytan, Eldrin F Lewis, Akshay S Desai, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
Pageof 76